Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States

• Autori principali: Sang Hee Park (Autore), Mark Lambton (Autore), Jordana Schmier (Autore), Sara Hovland (Autore), Keith Wittstock (Autore), Vardhaman Patel (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.Objective This study compared the cost per response (CPR) for US patients initiating deucravacitinib versus apremilast for modera...